Hyaluronidase and triamcinolone acetonide in treatment of keloid

Objective To explore and analyze the clinical value of hyaluronidase and triamcinolone acetonide in the treatment of keloid. Methods 100 patients with keloid admitted to our hospital from January, 2016 to December, 2018 were selected and divided into an observation group (51 cases) and a control group (49 cases) by random number table. The observation group were treated with hyaluronidase and triamcinolone acetonide, while the control group with triamcinolone acetonide. The clinical treatment effects, clinical indicators, and adverse reactions of the two groups were analyzed and compared. Results The cured rate, total effective rate, and the inefficiency rate of the observation group were 58.82% (30/51), 98.04% (50/51), and 1.96% (1/51), which were better than those in the control group, with statistical differences (all P<0.05). The height of scar tissue eminence, the pain score, and the pruritus score were (2.13±0.32) mm, (2.08±0.31) and (1.29±0.23) in the observation group, which were lower than those in the control group (all P<0.05). The total incidence of adverse reactions, such as premenstrual menstruation, pigmentation, and telangiectasia, was 7.84% (4/51) in the observation group, which was lower than that in the control group (P<0.05). Conclusion Hyaluronidase and triamcinolone acetonide keloid patients is effective and safe. Key words: Keloid; Hyaluronidase; Triamcinolone acetonide